GGrantIndex
← Leaderboards

Angela Rivers

University Of Florida

$2,882,643
Attributed
$2,882,643
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $437.3K · FY201023
$500K$375K$250K$125K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$2,882,643 · 3

By mechanism

R01$2,025,987 · 1
K01$696,756 · 1
R03$159,900 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Florida

Same institution · by research overlap

Others in their field

Top investigators on “United States

Research focus

United StatesAnemiaGenesMutationMouse ModelHematological DiseaseBone MarrowSickle Cell AnemiaChronicPainErythrocytesSicklingSickle HemoglobinPolymersEnvironmentClinical TrialsHematopoietic Stem CellsProteinsResearch PersonnelBeta GlobinEventAutophagocytosisDefectInherited

Grant awards (14)

The Role of Erythrocyte Mitochondrial Retention in Sickle Cell Disease$343,895
R01 · FY2023 · HL · contact PI
The Role of Erythrocyte Mitochondrial Retention in Sickle Cell Disease$93,404
R01 · FY2023 · HL · contact PI
The Role of Erythrocyte Mitochondrial Retention in Sickle Cell Disease$343,895
R01 · FY2022 · HL · contact PI
Diversity Supplement - The Role of Erythrocyte Mitochondrial Retention in Sickle Cell Disease$86,023
R01 · FY2022 · HL · contact PI
The Role of Erythrocyte Mitochondrial Retention in Sickle Cell Disease$359,270
R01 · FY2021 · HL · contact PI
The Role of Erythrocyte Mitochondrial Retention in Sickle Cell Disease$399,750
R01 · FY2020 · HL · contact PI
The Role of Erythrocyte Mitochondrial Retention in Sickle Cell Disease$399,750
R01 · FY2019 · HL · contact PI
Mitophagy as Potential Target in Sickle Cell Disease$79,950
R03 · FY2017 · HL · contact PI
Mitophagy as Potential Target in Sickle Cell Disease$79,950
R03 · FY2016 · HL · contact PI
Development of AAV vectors for the phenotypic correction of sickle cell disease$144,448
K01 · FY2014 · HL · contact PI
Development of AAV vectors for the phenotypic correction of sickle cell disease$144,448
K01 · FY2013 · HL · contact PI
Development of AAV vectors for the phenotypic correction of sickle cell disease$144,448
K01 · FY2012 · HL · contact PI
Development of AAV vectors for the phenotypic correction of sickle cell disease$131,706
K01 · FY2011 · HL · contact PI
Development of AAV vectors for the phenotypic correction of sickle cell disease$131,706
K01 · FY2010 · HL · contact PI